

United States Influenza Vaccines Market: Focus on Persons Vaccinated, Pricing, Production, Supply, Promising Influenza Vaccines, Clinical Trials, Regulatory, Reimbursement, Distribution Channel, Major Deals, Key Players, Recent Developments – Size, Share, Trends, Analysis, Demand, Opportunity, and Forecast, 2022 – 2030

<https://marketpublishers.com/r/U9B0A0438C65EN.html>

Date: February 2022

Pages: 220

Price: US\$ 3,450.00 (Single User License)

ID: U9B0A0438C65EN

Abstracts

The United States Influenza Vaccines market size is expected to reach USD 7,007 million by 2030. It is expected to expand at a CAGR of 6.9% from 2021 to 2030.

This new market report offerings an wide-ranging study of the entire United States influenza vaccines market. The report offers the most up-to-date industry data on the actual market situation and future outlook for the United States influenza vaccines market. The report also provides up-to-date market size data for the period 2015 - 2021 and an illustrative forecast to 2030 covering key market aspects like market value and volume for influenza vaccines.

This Newest and Comprehensive United States Influenza Vaccines Market Research Report 2022 Delivers:

The United States Influenza Vaccines Market Size, Insights, Analysis and Forecast, 2015-2030

The United States Number of Persons Vaccinated with Influenza Vaccines and Forecast, 2015 - 2030

Analyzes the United States Children Being Vaccinated with Influenza Vaccines and Forecast, 2015 - 2030

Analyzes the United States Adults Being Vaccinated with Influenza Vaccines and Forecast, 2015 - 2030

Key Market Growth Drivers and Challenges of the United States Influenza Vaccines Market

The United States Influenza Vaccines Pricing Analysis, Trends and Insights

The United States Influenza Vaccines Production, Supply, and Allocation (By Companies)

The United States Influenza Vaccines Distribution and Demand Analysis (2010 - 2021)

Examines the Effectiveness of the Influenza Vaccines in the United States (2004 – 2021)

Thoroughly Evaluates Rapid Diagnostic Testing for the Management of Influenza

Distribution Channel and Technique Detailed Insights of Influenza Vaccination in the United States

Reimbursement Environment of the United States Influenza Vaccines Market

Regulatory Framework of the United States Influenza Vaccines Market

Major Deals and Agreement Activities in the Influenza Vaccines Market

An Insightful Analysis of the Promising Influenza Vaccines in the Clinical Development

Analyses the Most Recent Clinical Trials of the Influenza Vaccines between 2020 and 2021

A Comprehensive List of the Key Players Along with the Analysis of their

Current Vaccines Portfolios, Promising Vaccines in the Clinical Development, Influenza Vaccines Market Value, and Recent Development

An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development

The Major and Emergent Market Players for the U.S Influenza Vaccines Market are Listed Below:

Sanofi Pasteur

GlaxoSmithKline (GSK)

Seqirus (CSL Limited)

AstraZeneca

Novavax

BiondVax Pharmaceuticals Ltd.

Medicago

Moderna Inc

Pneumagen

Daiichi-Sankyo

Altimune

FluGen

Imutex

Versatope Therapeutics, Inc

EpiVax, Inc

Key Questions Answered by this Latest 2022 Report:

What is the current scenario of the U.S. influenza vaccines market?

What is the total market size and forecast (until 2030) for the U.S. influenza vaccines market?

How many persons being vaccinated with influenza vaccines in the US during 2015 – 2027?

How effective is influenza(flu) shot for 2021?

What percentage of the United States do people get the flu vaccine?

What are the key marketed influenza vaccines available in the United States?

What are the major drivers of the United States influenza vaccines market?

What are the major inhibitors of the United States influenza vaccines market?

What is the reimbursement pattern in the United States influenza vaccines market?

What is the regulatory framework in the United States influenza vaccines market?

What are the major deals and agreement happenings in the United States influenza vaccines market?

What are the upcoming influenza vaccines that will have a significant impact on the market in the future?

Who are the top market players? What are their happenings, vaccine revenue, current developments, and scenarios?

Who are the emerging players? What are their happenings, clinical

development, platform technology, phase, and current developments?

How is the market predicted to develop in the future?

Contents

1. EXECUTIVE SUMMARY

2. UNITED STATES INFLUENZA VACCINES MARKET SIZE, INSIGHTS, ANALYSIS AND FORECASTS (2015 - 2030)

3. UNITED STATES NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINES (2015 - 2030)

3.1 Number of Children Vaccinated with Influenza Vaccines

3.2 Number of Adults Vaccinated with Influenza Vaccines

4. KEY MARKET GROWTH DRIVERS AND CHALLENGES OF THE UNITED STATES INFLUENZA VACCINES MARKET

4.1 Market Drivers

4.2 Market Challenges

5. UNITED STATES INFLUENZA VACCINES PRICING ANALYSIS, TRENDS AND INSIGHTS

6. UNITED STATES INFLUENZA VACCINES PRODUCTION, SUPPLY, AND ALLOCATION (BY COMPANIES)

7. UNITED STATES INFLUENZA VACCINES DISTRIBUTION AND DEMAND ANALYSIS (2010 - 2021)

8. EFFECTIVENESS OF INFLUENZA VACCINES IN THE UNITED STATES (2004 – 2021)

9. RAPID DIAGNOSTIC TESTING FOR THE MANAGEMENT OF INFLUENZA

10. DISTRIBUTION CHANNEL AND TECHNIQUE DETAILED INSIGHTS OF INFLUENZA VACCINATION IN THE UNITED STATES

11. REIMBURSEMENT ENVIRONMENT OF THE UNITED STATES INFLUENZA VACCINES MARKET

12. REGULATORY FRAMEWORK OF THE UNITED STATES INFLUENZA VACCINES MARKET

13. MAJOR DEALS AND AGREEMENT ACTIVITIES IN THE INFLUENZA VACCINES MARKET

- 13.1 Merger and Acquisitions
- 13.2 Collaboration Deals
- 13.3 Licensing Agreement
- 13.4 Exclusive Agreement
- 13.5 Distribution Agreement

14. PROMISING INFLUENZA VACCINES IN THE CLINICAL DEVELOPMENT

15. INFLUENZA VACCINES CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY AND COUNTRY

- 15.1 Year 2021
- 15.2 Year 2020

16. KEY PLAYERS ANALYSIS

- 16.1 Sanofi Pasteur
 - 16.1.1 Business Overview
 - 16.1.2 Influenza Vaccines Portfolio
 - 16.1.3 Influenza Vaccines Sales Value Analysis
 - 16.1.4 Promising Influenza Vaccines in the Clinical Development
 - 16.1.5 Recent Development
- 16.2 GlaxoSmithKline (GSK)
 - 16.2.1 Business Overview
 - 16.2.2 Influenza Vaccines Portfolio
 - 16.2.3 Influenza Vaccines Sales Value Analysis
 - 16.2.4 Recent Development
- 16.3 Seqirus
 - 16.3.1 Business Overview
 - 16.3.2 Influenza Vaccines Portfolios
 - 16.3.3 Influenza Vaccines Sales Value Analysis
 - 16.3.4 Promising Influenza Vaccines in the Clinical Development

16.3.5 Recent Development

16.4 AstraZeneca

16.4.1 Business Overview

16.4.2 Influenza Vaccines Portfolio

16.4.3 Influenza Vaccines Sales Value Analysis

16.4.4 Recent Development

17. EMERGING PLAYERS ANALYSIS

17.1 Novavax

17.1.1 Business Overview

17.1.2 Promising Influenza Vaccines in the Clinical Development

17.1.3 Recent Development

17.2 BiondVax Pharmaceuticals Ltd.

17.2.1 Business Overview

17.2.2 Promising Influenza Vaccines in the Clinical Development

17.2.3 Recent Development

17.3 Medicago

17.3.1 Business Overview

17.3.2 Promising Influenza Vaccines in the Clinical Development

17.3.3 Recent Development

17.4 Moderna Inc

17.4.1 Business Overview

17.4.2 Promising Influenza Vaccines in the Clinical Development

17.4.3 Recent Development

17.5 Pneumagen

17.5.1 Business Overview

17.5.2 Promising Influenza Vaccines in the Clinical Development

17.5.3 Recent Development

17.6 Altimune

17.6.1 Business Overview

17.6.2 Promising Influenza Vaccines in the Clinical Development

17.6.3 Recent Development

17.7 Daiichi Sankyo

17.7.1 Business Overview

17.7.2 Promising Influenza Vaccines in the Clinical Development

17.7.3 Recent Development

17.8 FluGen

17.8.1 Business Overview

17.8.2 Promising Influenza Vaccines in the Clinical Development

17.8.3 Recent Development

17.9 Imutex

17.9.1 Business Overview

17.9.2 Promising Vaccines in the Clinical Development

17.9.3 Recent Development

17.10 EpiVax

17.10.1 Business Overview

17.10.2 Promising Influenza Vaccines in the Clinical Development

17.10.3 Recent Development

17.11 Versatope Therapeutics, Inc.

17.11.1 Business Overview

17.11.2 Promising Influenza Vaccines in the Clinical Development

17.11.3 Recent Development

List Of Tables

LIST OF TABLES:

Table 5–1: United States Pediatric Influenza Vaccines Price, 2021 – 2022

Table 5–2: United States Adult Influenza Vaccines Price, 2021 – 2022

Table 6–1: United States Influenza Vaccines Production, Supply, and Allocation

Table 7–1: Total Percentage of Influenza Vaccines Released by Week, 2021 – 2022

Table 7–1: Total Percentage of Influenza Vaccines Released by Week, 2020 – 2021

Table 7–2: Total Percentage of Influenza Vaccines Released by Week, 2019 – 2020

Table 7–3: Total Percentage of Influenza Vaccines Released by Week, 2018 – 2019

Table 7–4: Total Percentage of Influenza Vaccines Released by Week, 2017 – 2018

Table 7–5: Total Percentage of Influenza Vaccines Released by Week, 2016 – 2017

Table 7–6: Total Percentage of Influenza Vaccines Released by Week, 2015 – 2016

Table 7–7: Total Percentage of Influenza Vaccines Released by Week, 2014 – 2015

Table 8–1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2021

Table 9–1: Influenza Virus Testing Methods

Table 10–1: Distribution of Influenza Vaccination

Table 12–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization

Table 13–1: Merger & Acquisitions in the Influenza Vaccines Market

Table 13–2: Collaboration Deal in the Influenza Vaccines Market

Table 13–3: Licensing Agreement in the Influenza Vaccines Market

Table 13–4: Exclusive Agreement in the Influenza Vaccines Market

Table 13–5: Distribution Agreement in the Influenza Vaccines Market

Table 14–1: BiondVax Pharmaceuticals Ltd. – Clinical Trials

Table 16–1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development

Table 16–2: Seqirus Promising Influenza Vaccines in the Clinical Development

Table 17–1: Novavax Promising Influenza Vaccines in the Clinical Development

Table 17–2: BiondVax Promising Influenza Vaccines in the Clinical Development

Table 17–3: Medicago Promising Influenza Vaccines in the Clinical Development

Table 17–4: Moderna Promising Influenza Vaccines in the Clinical Development

Table 17–5: Pneumagen Promising Influenza Vaccines in the Clinical Development

Table 17–6: Altimune Promising Influenza Vaccines in the Clinical Development

Table 17–7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development

Table 17–8: FluGen Promising Influenza Vaccines in the Clinical Development

Table 17–9: Imutex Promising Influenza Vaccines in the Clinical Development

Table 12–10: EpiVax Promising Influenza Vaccines in the Clinical Development

Table 12–11: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development

List Of Figures

LIST OF FIGURES:

Figure 2–1: United States Influenza Vaccines Market Size and Analysis (Million US\$),2015 – 2021

Figure 2–2: United States Influenza Vaccines Market Size and Forecast (Million US\$),2022 – 2030

Figure 3–1: United States Total Number of Individuals Vaccinated with Influenza Vaccines (Thousand), 2015 – 2021

Figure 3–2: United States Total Number of Individuals Vaccinated with Influenza Vaccines Forecast (Thousand), 2022 – 2030

Figure 3–3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2015 – 2021

Figure 3–4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2022 – 2030

Figure 3–5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2015 – 2021

Figure 3–6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2022 – 2030

Figure 7–1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2021

Figure 10–1: United States Place of Influenza Vaccination for Children and Adults (Percent),2019 - 2020

Figure 16–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US\$),2015 – 2021

Figure 16–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US\$),2022 – 2030

Figure 16–3: GSK Influenza Vaccines Net Sales Value (Million US\$),2015 – 2021

Figure 16–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US\$),2022 – 2030

Figure 16–5: Seqirus Influenza Vaccines Net Sales Value (Million US\$),2015 – 2021

Figure 16–6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US\$),2022 – 2030

Figure 16–7: AstraZeneca Influenza Vaccines Net Sales Value (Million US\$),2015 – 2021

Figure 16–8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US\$),2022 – 2030

I would like to order

Product name: United States Influenza Vaccines Market: Focus on Persons Vaccinated, Pricing, Production, Supply, Promising Influenza Vaccines, Clinical Trials, Regulatory, Reimbursement, Distribution Channel, Major Deals, Key Players, Recent Developments – Size, Share, Trends, Analysis, Demand, Opportunity, and Forecast, 2022 – 2030

Product link: <https://marketpublishers.com/r/U9B0A0438C65EN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U9B0A0438C65EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970